Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Sep
23
Today In Oncology
Excess Mortality Halts Trial of Venetoclax Added to DA-EPOCH-R in Double-Hit Lymphoma
Germline EGFR T790M Associated With Significant Lung Cancer Risk
Second-Line Investigational Monoclonal Antibody in Metastatic Squamous NSCLC
Neoadjuvant Anbenitamab/Chemotherapy Combination Improves Response in ERBB2-Positive Breast Cancer
ASCO Breakthrough Studies Target Supportive Care Problems That Can Derail Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo